Journal article
Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial
Abstract
PURPOSE: Recent studies suggest that intrinsic breast cancer subtypes may differ in their responsiveness to specific chemotherapy regimens. We examined this hypothesis on NCIC.CTG MA.5, a clinical trial randomizing premenopausal women with node-positive breast cancer to adjuvant CMF (cyclophosphamide-methotrexate-fluorouracil) versus CEF (cyclophosphamide-epirubicin-fluorouracil) chemotherapy.
EXPERIMENTAL DESIGN: Intrinsic subtype was …
Authors
Cheang MCU; Voduc KD; Tu D; Jiang S; Leung S; Chia SK; Shepherd LE; Levine MN; Pritchard KI; Davies S
Journal
Clinical Cancer Research, Vol. 18, No. 8, pp. 2402–2412
Publisher
American Association for Cancer Research (AACR)
Publication Date
April 15, 2012
DOI
10.1158/1078-0432.ccr-11-2956
ISSN
1078-0432